This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines. Founded in 2015, the firm is working on cancer vaccines that use a viral vector platform to train the immune system to recognize and attack cancer. The company is developing both personalized and off-the-shelf approaches, aiming to treat a range of tumors. Before taking the helm at Nouscom, Dr Udier built a diverse career across healthcare — working ...
All content for The Pharma Letter Podcast is the property of Simon Wentworth and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines. Founded in 2015, the firm is working on cancer vaccines that use a viral vector platform to train the immune system to recognize and attack cancer. The company is developing both personalized and off-the-shelf approaches, aiming to treat a range of tumors. Before taking the helm at Nouscom, Dr Udier built a diverse career across healthcare — working ...
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. Pointing to the high levels of innovation in the USA, a country where new drugs and biologics tend to get launched first, argue that market-based pricing funds essential research and development. As the US Congress debates more government intervention to improve access, including the potential for the federal insurance fund Medicare to actively negotiate drug prices, one ...
The Pharma Letter Podcast
This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines. Founded in 2015, the firm is working on cancer vaccines that use a viral vector platform to train the immune system to recognize and attack cancer. The company is developing both personalized and off-the-shelf approaches, aiming to treat a range of tumors. Before taking the helm at Nouscom, Dr Udier built a diverse career across healthcare — working ...
